JP2020012000A5 - - Google Patents

Download PDF

Info

Publication number
JP2020012000A5
JP2020012000A5 JP2019194124A JP2019194124A JP2020012000A5 JP 2020012000 A5 JP2020012000 A5 JP 2020012000A5 JP 2019194124 A JP2019194124 A JP 2019194124A JP 2019194124 A JP2019194124 A JP 2019194124A JP 2020012000 A5 JP2020012000 A5 JP 2020012000A5
Authority
JP
Japan
Prior art keywords
cancer
composition according
chimeric receptor
pharmaceutical composition
mesocerine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019194124A
Other languages
English (en)
Japanese (ja)
Other versions
JP6944497B2 (ja
JP2020012000A (ja
Filing date
Publication date
Priority claimed from JP2017131791A external-priority patent/JP2017184759A/ja
Application filed filed Critical
Publication of JP2020012000A publication Critical patent/JP2020012000A/ja
Publication of JP2020012000A5 publication Critical patent/JP2020012000A5/ja
Application granted granted Critical
Publication of JP6944497B2 publication Critical patent/JP6944497B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019194124A 2008-04-09 2019-10-25 新規に単離された細胞の治療組成物の操作および送達 Active JP6944497B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4365308P 2008-04-09 2008-04-09
US61/043,653 2008-04-09
JP2017131791A JP2017184759A (ja) 2008-04-09 2017-07-05 新規に単離された細胞の治療組成物の操作および送達

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017131791A Division JP2017184759A (ja) 2008-04-09 2017-07-05 新規に単離された細胞の治療組成物の操作および送達

Publications (3)

Publication Number Publication Date
JP2020012000A JP2020012000A (ja) 2020-01-23
JP2020012000A5 true JP2020012000A5 (https=) 2020-09-17
JP6944497B2 JP6944497B2 (ja) 2021-10-06

Family

ID=41162602

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2011504171A Active JP5779090B2 (ja) 2008-04-09 2009-04-09 新規に単離された細胞の治療組成物の操作および送達
JP2015138578A Active JP6630074B2 (ja) 2008-04-09 2015-07-10 新規に単離された細胞の治療組成物の操作および送達
JP2017131791A Pending JP2017184759A (ja) 2008-04-09 2017-07-05 新規に単離された細胞の治療組成物の操作および送達
JP2019194124A Active JP6944497B2 (ja) 2008-04-09 2019-10-25 新規に単離された細胞の治療組成物の操作および送達

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2011504171A Active JP5779090B2 (ja) 2008-04-09 2009-04-09 新規に単離された細胞の治療組成物の操作および送達
JP2015138578A Active JP6630074B2 (ja) 2008-04-09 2015-07-10 新規に単離された細胞の治療組成物の操作および送達
JP2017131791A Pending JP2017184759A (ja) 2008-04-09 2017-07-05 新規に単離された細胞の治療組成物の操作および送達

Country Status (5)

Country Link
US (8) US8450112B2 (https=)
EP (1) EP2279253B1 (https=)
JP (4) JP5779090B2 (https=)
DK (1) DK2279253T3 (https=)
WO (1) WO2009126789A2 (https=)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008097926A2 (en) * 2007-02-02 2008-08-14 Yale University Transient transfection with rna
US10155038B2 (en) 2007-02-02 2018-12-18 Yale University Cells prepared by transient transfection and methods of use thereof
US9249423B2 (en) 2007-02-02 2016-02-02 Yale University Method of de-differentiating and re-differentiating somatic cells using RNA
US8450112B2 (en) * 2008-04-09 2013-05-28 Maxcyte, Inc. Engineering and delivery of therapeutic compositions of freshly isolated cells
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
JP5989016B2 (ja) * 2011-06-24 2016-09-07 国立大学法人九州大学 Nk細胞の増幅方法
JP5572863B2 (ja) * 2011-06-24 2014-08-20 国立大学法人九州大学 Nk細胞の増幅方法
CN103946952A (zh) 2011-09-16 2014-07-23 宾夕法尼亚大学董事会 用于治疗癌症的rna改造的t细胞
US9272002B2 (en) 2011-10-28 2016-03-01 The Trustees Of The University Of Pennsylvania Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
EP2828290B1 (en) 2012-03-23 2018-08-15 The United States of America, represented by the Secretary, Department of Health and Human Services Anti-mesothelin chimeric antigen receptors
EP4282419A1 (en) 2012-12-20 2023-11-29 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
US10144770B2 (en) 2013-10-17 2018-12-04 National University Of Singapore Chimeric receptors and uses thereof in immune therapy
US10611837B2 (en) 2014-04-10 2020-04-07 Seattle Children's Hospital Transgene genetic tags and methods of use
WO2016095934A2 (en) * 2014-12-14 2016-06-23 El Abd Hisham Mohamed Magdy A novel genetic device to engineer cell behavior
WO2016123578A1 (en) 2015-01-30 2016-08-04 The Regents Of The University Of California Protein delivery in primary hematopoietic cells
US12577289B2 (en) 2015-06-30 2026-03-17 Arizona Board Of Regents On Behalf Of The University Of Arizona Surrogate co-receptors for t cells and methods of use
US11059880B2 (en) 2015-06-30 2021-07-13 Arizona Board Of Regents On Behalf Of The University Of Arizona Redirected cells with MHC chimeric receptors and methods of use in immunotherapy
IL315940A (en) 2015-07-28 2024-11-01 Univ Pennsylvania Altered monocytes/macrophages expressing chimeric antigen receptors and their uses
AU2016306209B2 (en) 2015-08-07 2023-07-06 Seattle Children's Hospital (dba Seattle Children's Research Institute) Bispecific CAR T-cells for solid tumor targeting
AU2016361451B2 (en) 2015-11-27 2024-01-25 Cartherics Pty. Ltd. Genetically modified cells and uses thereof
EP3439675A4 (en) 2016-04-08 2019-12-18 Purdue Research Foundation METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY
US11293021B1 (en) 2016-06-23 2022-04-05 Inscripta, Inc. Automated cell processing methods, modules, instruments, and systems
US11408005B2 (en) 2016-12-12 2022-08-09 Seattle Children's Hospital Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
US11649288B2 (en) 2017-02-07 2023-05-16 Seattle Children's Hospital Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
EP3612210A4 (en) 2017-04-19 2021-01-27 Board Of Regents, The University Of Texas System MANIPULATED ANTIGEN RECEPTORS EXPRESSING IMMUNE CELLS
WO2018232356A1 (en) 2017-06-15 2018-12-20 The Regents Of The University Of California Targeted non-viral dna insertions
US9982279B1 (en) 2017-06-23 2018-05-29 Inscripta, Inc. Nucleic acid-guided nucleases
US10011849B1 (en) 2017-06-23 2018-07-03 Inscripta, Inc. Nucleic acid-guided nucleases
JP2020530979A (ja) 2017-06-30 2020-11-05 インスクリプタ, インコーポレイテッド 自動細胞処理方法、モジュール、機器及びシステム
JP2020530280A (ja) * 2017-07-03 2020-10-22 トルク セラピューティクス, インコーポレイテッド 免疫刺激性融合分子およびその使用
US10738327B2 (en) 2017-08-28 2020-08-11 Inscripta, Inc. Electroporation cuvettes for automation
CN111065399B (zh) 2017-09-01 2023-11-28 Gpb科学有限公司 使用微流体制备治疗活性细胞的方法
JP6985508B2 (ja) 2017-09-30 2021-12-22 インスクリプタ, インコーポレイテッド フロースルーエレクトロポレーション機器編成
JP7101419B2 (ja) 2017-10-27 2022-07-15 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 内因性t細胞受容体の標的置換
WO2019090355A1 (en) * 2017-11-06 2019-05-09 Children's National Medical Center Cells expressing antibodies and methods of treatment using the same
EP3735255A4 (en) * 2018-01-05 2021-09-22 Maxcyte, Inc. CHRONIC CANCER TREATMENT BY CARS
US11311576B2 (en) 2018-01-22 2022-04-26 Seattle Children's Hospital Methods of use for CAR T cells
US12312416B2 (en) 2018-02-06 2025-05-27 Seattle Children's Hospital Fluorescein-specific cars exhibiting optimal t cell function against FL-PLE labelled tumors
BR112020016176A2 (pt) * 2018-02-09 2022-02-22 Immatics Us Inc Métodos de transdução de uma célula t, célula t transduzida geneticamente, composição farmacêutica, métodos de preparação de uma população de células t e uso da célula t
US12473336B2 (en) 2018-02-21 2025-11-18 Board Of Regents, The University Of Texas System Methods for activation and expansion of natural killer cells and uses thereof
AU2019225174B2 (en) 2018-02-23 2025-11-20 Endocyte, Inc. Sequencing method for CAR T cell therapy
US10443031B1 (en) 2018-03-29 2019-10-15 Inscripta, Inc. Methods for controlling the growth of prokaryotic and eukaryotic cells
WO2019200004A1 (en) 2018-04-13 2019-10-17 Inscripta, Inc. Automated cell processing instruments comprising reagent cartridges
US10858761B2 (en) 2018-04-24 2020-12-08 Inscripta, Inc. Nucleic acid-guided editing of exogenous polynucleotides in heterologous cells
WO2019209926A1 (en) 2018-04-24 2019-10-31 Inscripta, Inc. Automated instrumentation for production of peptide libraries
US10557216B2 (en) 2018-04-24 2020-02-11 Inscripta, Inc. Automated instrumentation for production of T-cell receptor peptide libraries
CA3108767A1 (en) 2018-06-30 2020-01-02 Inscripta, Inc. Instruments, modules, and methods for improved detection of edited sequences in live cells
WO2020014235A1 (en) 2018-07-09 2020-01-16 The Regents Of The University Of California Gene targets for t-cell-based immunotherapy
US11142740B2 (en) 2018-08-14 2021-10-12 Inscripta, Inc. Detection of nuclease edited sequences in automated modules and instruments
US10532324B1 (en) 2018-08-14 2020-01-14 Inscripta, Inc. Instruments, modules, and methods for improved detection of edited sequences in live cells
JP7456638B2 (ja) 2018-08-14 2024-03-27 ソティオ,リミティド ライアビリティ カンパニー クレブス回路を調節するトランス代謝分子と組み合わせたキメラ抗原受容体ポリペプチド、及び、それらの治療的使用
WO2020081149A2 (en) 2018-08-30 2020-04-23 Inscripta, Inc. Improved detection of nuclease edited sequences in automated modules and instruments
KR20210056377A (ko) * 2018-09-07 2021-05-18 소티오, 엘엘씨 세포내 락테이트 농도를 조절하는 트랜스 대사 분자와 조합된 키메라 수용체 폴리펩타이드 및 이의 치료 용도
EP3868783A4 (en) * 2018-10-19 2022-01-19 Cartexell Inc. ANTI-L1CAM ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AND CHIMERIC ANTIGEN RECEPTOR THEREOF
WO2020086475A1 (en) 2018-10-22 2020-04-30 Inscripta, Inc. Engineered enzymes
US11214781B2 (en) 2018-10-22 2022-01-04 Inscripta, Inc. Engineered enzyme
CN111349615B (zh) * 2018-12-24 2024-08-13 上海细胞治疗集团股份有限公司 制备过表达外源基因的细胞的方法
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
AU2020247900A1 (en) 2019-03-25 2021-11-04 Inscripta, Inc. Simultaneous multiplex genome editing in yeast
US11001831B2 (en) 2019-03-25 2021-05-11 Inscripta, Inc. Simultaneous multiplex genome editing in yeast
AU2020288623A1 (en) 2019-06-06 2022-01-06 Inscripta, Inc. Curing for recursive nucleic acid-guided cell editing
WO2020257395A1 (en) 2019-06-21 2020-12-24 Inscripta, Inc. Genome-wide rationally-designed mutations leading to enhanced lysine production in e. coli
US10927385B2 (en) 2019-06-25 2021-02-23 Inscripta, Inc. Increased nucleic-acid guided cell editing in yeast
US11203762B2 (en) 2019-11-19 2021-12-21 Inscripta, Inc. Methods for increasing observed editing in bacteria
CA3157131A1 (en) 2019-12-10 2021-06-17 Inscripta, Inc. Novel mad nucleases
US10704033B1 (en) 2019-12-13 2020-07-07 Inscripta, Inc. Nucleic acid-guided nucleases
AU2020407048A1 (en) 2019-12-18 2022-06-09 Inscripta, Inc. Cascade/dCas3 complementation assays for in vivo detection of nucleic acid-guided nuclease edited cells
US10689669B1 (en) 2020-01-11 2020-06-23 Inscripta, Inc. Automated multi-module cell processing methods, instruments, and systems
US11225674B2 (en) 2020-01-27 2022-01-18 Inscripta, Inc. Electroporation modules and instrumentation
CN115210252A (zh) 2020-02-04 2022-10-18 西雅图儿童医院(Dba西雅图儿童研究所) 抗二硝基苯酚的嵌合抗原受体
US20210332388A1 (en) 2020-04-24 2021-10-28 Inscripta, Inc. Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells
US11787841B2 (en) 2020-05-19 2023-10-17 Inscripta, Inc. Rationally-designed mutations to the thrA gene for enhanced lysine production in E. coli
EP4161536A4 (en) 2020-06-04 2024-08-14 Carisma Therapeutics Inc. Novel constructs for chimeric antigen receptors
US11299731B1 (en) 2020-09-15 2022-04-12 Inscripta, Inc. CRISPR editing to embed nucleic acid landing pads into genomes of live cells
US11512297B2 (en) 2020-11-09 2022-11-29 Inscripta, Inc. Affinity tag for recombination protein recruitment
AU2021415461A1 (en) 2021-01-04 2023-08-17 Inscripta, Inc. Mad nucleases
EP4274890A4 (en) 2021-01-07 2024-11-27 Inscripta, Inc. MAD-NUCLEASES
US11884924B2 (en) 2021-02-16 2024-01-30 Inscripta, Inc. Dual strand nucleic acid-guided nickase editing
JP2024537991A (ja) 2021-10-14 2024-10-18 アーセナル バイオサイエンシズ インコーポレイテッド 共発現されるshRNAと論理ゲートシステムとを有する免疫細胞
EP4279085A1 (en) 2022-05-20 2023-11-22 Mnemo Therapeutics Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease
PE20251319A1 (es) 2022-09-13 2025-05-16 Arsenal Biosciences Inc Celulas inmunitarias que coexpresan arnhc de tgfbr
EP4587570A2 (en) 2022-09-16 2025-07-23 Arsenal Biosciences, Inc. Immune cells with combination gene perturbations
IL322949A (en) 2023-03-03 2025-10-01 Arsenal Biosciences Inc Systems targeting PSMA and CA9
IL322838A (en) 2023-03-13 2025-10-01 Arsenal Biosciences Inc Synthetic pathway operators
AU2024260837A1 (en) 2023-04-25 2025-10-16 Arsenal Biosciences, Inc. Novel receptors for transcription regulation
WO2024233494A2 (en) * 2023-05-05 2024-11-14 Cellfe, Inc. Methods and systems for rapid engineering of resting cells
WO2024259299A1 (en) 2023-06-14 2024-12-19 The Broad Institute, Inc. Compositions and methods for identification of vhh antibodies that bind a target antigen
WO2024259305A1 (en) 2023-06-14 2024-12-19 The Broad Institute, Inc. Vhh polypeptides that bind to mesothelin, compositions and methods of use thereof
WO2025199346A1 (en) 2024-03-20 2025-09-25 Arsenal Biosciences, Inc. Antigen binding proteins that bind tmprss4 and methods of use thereof
WO2026055342A1 (en) 2024-09-04 2026-03-12 Arsenal Biosciences, Inc. Synthetic pathway activators
WO2026076388A1 (en) 2024-10-03 2026-04-09 The Broad Institute, Inc. Vhh polypeptides that bind to claudin-18, compositions and methods of use thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
DE4228457A1 (de) 1992-08-27 1994-04-28 Beiersdorf Ag Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen
JPH08511680A (ja) * 1993-03-23 1996-12-10 シービーアール・ラボラトリーズ・インコーポレーテツド 細胞内への生物学的活性物質の封入のための方法および装置
FR2722208B1 (fr) 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
US6103521A (en) * 1995-02-06 2000-08-15 Cell Genesys, Inc. Multispecific chimeric receptors
US5720921A (en) * 1995-03-10 1998-02-24 Entremed, Inc. Flow electroporation chamber and method
US6773669B1 (en) 1995-03-10 2004-08-10 Maxcyte, Inc. Flow electroporation chamber and method
US6074605A (en) * 1995-03-10 2000-06-13 Entremed, Inc. Flow electroporation chamber and method
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US6090617A (en) 1996-12-05 2000-07-18 Entremed, Inc. Flow electroporation chamber with electrodes having a crystalline metal nitride coating
GB0025307D0 (en) 2000-10-16 2000-11-29 Celltech Chiroscience Ltd Biological products
ATE338124T1 (de) 2000-11-07 2006-09-15 Hope City Cd19-spezifische umgezielte immunzellen
US7029916B2 (en) * 2001-02-21 2006-04-18 Maxcyte, Inc. Apparatus and method for flow electroporation of biological samples
US7723111B2 (en) * 2001-03-09 2010-05-25 The United States Of America As Represented By The Department Of Health And Human Services Activated dual specificity lymphocytes and their methods of use
AU2002326717A1 (en) 2001-08-22 2003-03-10 Maxcyte, Inc. Apparatus and method for electroporation of biological samples
WO2004031353A2 (en) 2002-09-30 2004-04-15 Maxcyte, Inc. Apparatus and method for streaming electroporation
WO2004074451A2 (en) * 2003-02-18 2004-09-02 Maxcyte, Inc. Loading of cells with antigens by electroporation
WO2006063301A1 (en) * 2004-12-10 2006-06-15 Maxcyte, Inc. Genetically modified tumor cells as cancer vaccines
EP1795599A1 (en) 2005-12-09 2007-06-13 Schuler, Gerold, Prof. Dr. Methods for generating antigen-specific effector T cells
WO2008097926A2 (en) * 2007-02-02 2008-08-14 Yale University Transient transfection with rna
SI2856876T1 (en) * 2007-03-30 2018-04-30 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
US8450112B2 (en) 2008-04-09 2013-05-28 Maxcyte, Inc. Engineering and delivery of therapeutic compositions of freshly isolated cells
KR101076879B1 (ko) 2008-04-11 2011-10-25 주식회사 하이닉스반도체 셀프 부스팅을 이용한 플래시 메모리소자의 프로그램 방법
WO2012050374A2 (en) 2010-10-13 2012-04-19 Innocell, Inc. Immunotherapy for solid tumors
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
EP3783098A1 (en) 2013-05-14 2021-02-24 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
EP4166148B1 (en) 2014-06-06 2026-02-18 Memorial Sloan-Kettering Cancer Center Mesothelin-targeted chimeric antigen receptors and uses thereof
CU24649B1 (es) 2016-03-19 2023-02-13 Exuma Biotech Corp Retrovirus recombinantes incompetentes de replicación para la transducción de linfocitos y expansión regulada de los mismos
EP3735255A4 (en) 2018-01-05 2021-09-22 Maxcyte, Inc. CHRONIC CANCER TREATMENT BY CARS

Similar Documents

Publication Publication Date Title
JP2020012000A5 (https=)
JP2019534246A5 (https=)
Yoon et al. Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model
Kudo et al. T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing
Cho et al. Cytotoxicity of activated natural killer cells against pediatric solid tumors
JP2023502503A5 (https=)
WO2023020423A1 (en) Ror1 car or ror1 /cd19 dual car t cells for the treatment of tumors
JP2021502070A5 (https=)
JP2020500530A5 (https=)
JP2020513828A5 (https=)
TW202000691A (zh) 嵌合跨膜蛋白及其用途
JP2019532953A5 (https=)
US10821162B2 (en) Use of car and bite technology coupled with an SCFV from an antibody against human thymidine kinase 1 to specifically target tumors
JP2019518425A5 (https=)
JP2020506700A5 (https=)
JP2017518052A5 (https=)
CN113811327A (zh) MUC1平行CAR(pCAR)治疗剂
JP2018522567A5 (https=)
JP2015527070A5 (https=)
JP2018527008A5 (https=)
RU2017100003A (ru) Улучшенные композиции на основе t-клеток
RU2018127657A (ru) Виды терапии на основе иммуноэффекторных клеток с улучшенной эффективностью
CN105153315A (zh) 免疫抑制受体联合肿瘤抗原嵌合受体及其应用
HRP20200978T1 (hr) Poboljšani postupci terapije proizvodnjom adoptivnih stanica
JP2017513470A5 (https=)